L. Martin

发表

A retrospective, multicenter study of the tolerance of induction chemotherapy with docetaxel, Cisplatin, and 5-Fluorouracil followed by radiotherapy with concomitant cetuximab in 46 cases of squamous cell carcinoma of the head and neck.

R. Écochard, J. Fayette, P. Pommier, 2010, International journal of radiation oncology, biology, physics.

Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial.

J. Prevost, C. Sire, X. Sun, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Very accelerated radiotherapy or concurrent chemoradiotherapy for N3 head and neck squamous cell carcinoma: Pooled analysis of two GORTEC randomized trials.

V. Grégoire, G. Calais, J. Bourhis, 2017, Oral oncology.

All-trans retinoic acid in relapsing malignant gliomas: clinical and radiological stabilization associated with the appearance of intratumoral calcifications

J. Degos, F. Ricolfi, H. Adle-Biassette, 1997, Journal of Neuro-Oncology.

Induction Chemotherapy Followed by Cetuximab Radiotherapy Is Not Superior to Concurrent Chemoradiotherapy for Head and Neck Carcinomas: Results of the GORTEC 2007-02 Phase III Randomized Trial.

J. Bourhis, E. Babin, C. Borel, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Afatinib maintenance therapy following post-operative radiochemotherapy in head and neck squamous cell carcinoma: Results from the phase III randomised double-blind placebo-controlled study BIB2992ORL (GORTEC 2010-02).

C. Sire, P. Fournel, Y. Tao, 2022, European journal of cancer.

Avelumab-cetuximab-radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH).

J. Bourhis, J. Thariat, C. Sire, 2020, European journal of cancer.

Avelumab-cetuximab-radiotherapy (RT) versus standards of care (SoC) in locally advanced squamous cell carcinoma of the head and neck (SCCHN): Safety phase of the randomized trial GORTEC 2017-01 (REACH).

J. Bourhis, C. Sire, A. Aupérin, 2018 .

Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy.

G. Calais, J. Bourhis, É. Bardet, 2002, Seminars in oncology.

Low-level laser therapy in treatment of chemoradiotherapy-induced mucositis in head and neck cancer: results of a randomised, triple blind, multicentre phase III trial

G. Calais, U. Schick, O. Capitain, 2019, Radiation Oncology.

[Recurrence of upper aerodigestive tract tumors].

Mustapha Zoubir, Laurent Martin, C. le Tourneau, 2014, Bulletin du cancer.

Subcutaneous compared with intravenous administration of amifostine in patients with head and neck cancer receiving radiotherapy: final results of the GORTEC2000-02 phase III randomized trial.

G. Calais, J. Bourhis, P. Garaud, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.

J. Bourhis, C. Sire, A. Aupérin, 2021, The Lancet. Oncology.

Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial.

N. Magné, B. Chauffert, F. Clatot, 2023, European journal of cancer.

Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study.

N. Magné, B. Chauffert, J. Bourhis, 2020, The Lancet. Oncology.

Phase II study of preoperative radiation plus concurrent daily tegafur-uracil (UFT) with leucovorin for locally advanced rectal cancer

G. Calais, E. Gamelin, M. Boisdron-Celle, 2011, BMC Cancer.

Concomitant chemoradiotherapy using carboplatin, tegafur-uracil and leucovorin for stage III and IV head-and-neck cancer: results of GORTEC Phase II study.

G. Calais, P. Garaud, P. Pommier, 2010, International journal of radiation oncology, biology, physics.

Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial.

V. Grégoire, G. Calais, J. Bourhis, 2012, The Lancet. Oncology.

LBA38 Pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Results of the GORTEC 2015-01 “PembroRad” randomized trial

J. Bourhis, J. Prevost, C. Sire, 2020, Annals of Oncology.

Improved Outcome by Adding Concurrent Chemotherapy to Cetuximab and Radiotherapy for Locally Advanced Head and Neck Carcinomas: Results of the GORTEC 2007-01 Phase III Randomized Trial.

J. Bourhis, C. Borel, P. Maingon, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oxygen tension measurements in human tumors: The institut gustave-roussy experience

C. Haie-meder, A. Gerbaulet, F. Eschwège, 1993 .

Prolonged survival for patients with newly diagnosed, inoperable glioblastoma with 3-times daily ultrafractionated radiation therapy.

R. Stupp, T. Gorlia, T. Khalil, 2010, Neuro-oncology.

Impact of p16 expression on induction taxotere-cisplatin-5 FU (TPF) followed by cetuximab-radiotherapy in N2b-N3 head and neck squamous cell carcinoma (HNSCC): Results of GORTEC 2007-02 phase III randomized trial.

J. Bourhis, E. Babin, P. Maingon, 2017 .

Oxygenation of head and neck tumors

P. Lambin, F. Eschwège, B. Luboinski, 1993, Cancer.

A phase II randomized trial of pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN): First results of the GORTEC 2015-01 “PembroRad” trial.

J. Bourhis, J. Prevost, C. Sire, 2018 .

TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

C. Sire, A. Aupérin, O. Capitain, 2019, Journal of Clinical Oncology.

Accelerated versus Conventional Radiotherapy with Concomitant Chemotherapy in Locally Advanced Head and Neck Carcinomas: Results of a Phase III Randomized Trial

V. Grégoire, G. Calais, J. Bourhis, 2008 .